RESEARCH · TIRZEPATIDE · BODY COMPOSITION
Tirzepatide Beyond the Scale: Body Composition, Liver Fat and Heart-Failure Studies in the Trial Literature
Our earlier article, Tirzepatide: dual GIP/GLP-1 mechanism and the SURPASS/SURMOUNT programme, covered how the peptide works and the headline glycaemic and weight-loss trials. This article looks at the secondary literature: imaging and tissue-composition substudies that ask what the weight lost is made of, what happens to liver fat, and what the first heart-failure outcome trial reported. PurixLab’s Tirzepatide 10mg is supplied as a research material for laboratory research use only; the studies below describe a clinical drug product under trial conditions.
What the weight is made of
In SURMOUNT-1, 2539 adults with obesity were followed for 72 weeks; mean weight change across the three tirzepatide groups ranged from 15.0% to 20.9%, against 3.1% with placebo [1]. A DXA substudy of 160 of those participants (124 on tirzepatide, 36 on placebo) found that at week 72 body weight fell 21.3%, fat mass 33.9% and lean mass 10.9% with tirzepatide, versus 5.3%, 8.2% and 2.6% with placebo. Of the weight lost, about 75% was fat mass and 25% lean mass, in both groups [2].
That 25% figure recurs in the wider literature. A network meta-analysis of 22 randomised trials (2258 participants) estimated that lean-mass loss comprised about 25% of the total weight lost with GLP-1 receptor agonists, while relative lean mass (percentage change from baseline) was unaffected. Tirzepatide and semaglutide were among the most effective for weight and fat-mass reduction but also among the least effective at preserving lean mass [3]. A 2026 systematic review of 35 studies could not pool them, because methods varied, but reported that the median share of weight loss attributable to muscle-based indices was 28.3%, with 65% exceeding its benchmark of about 25%; nearly half of non-drug interventions also exceeded their benchmark, and no study reported objective physical-function outcomes [4].
Muscle quality on MRI
In a post hoc analysis of the SURPASS-3 MRI substudy in type 2 diabetes, 246 participants had a valid week-52 scan. Thigh muscle fat infiltration and muscle volume both fell with tirzepatide. Against UK Biobank-based estimates (n=2942) of what would be expected for the weight change, the muscle-volume change was similar, while the fall in muscle fat infiltration was significantly greater. The authors described the changes in muscle fat infiltration as potentially favourable, the muscle-volume reduction as broadly in line with the general association with weight change, and the analysis as post hoc and exploratory [5].
Liver fat and MASH histology
The SURPASS-3 MRI substudy enrolled 296 participants with a fatty liver index of at least 60. Mean liver fat content was 15.71% at baseline; by week 52 the absolute reduction was 8.09 percentage points in the pooled higher-exposure tirzepatide groups against 3.38 with insulin degludec (estimated difference 4.71, 95% CI 2.70 to 6.72). Reductions correlated with baseline liver fat and with reductions in visceral and subcutaneous abdominal fat and body weight [6].
SYNERGY-NASH was a phase 2 trial in biopsy-confirmed MASH with F2–F3 fibrosis: 190 participants were randomised and 157 had evaluable biopsies at week 52. Resolution of MASH without worsening of fibrosis occurred in 10% on placebo and in 44%, 56% and 62% across the three tirzepatide groups. At least one stage of fibrosis improvement without worsening of MASH occurred in 30% on placebo and 55%, 51% and 51% on tirzepatide. Gastrointestinal events were most common, and the authors stated that larger and longer trials are needed [7].
Heart failure with preserved ejection fraction
SUMMIT randomised 731 patients with heart failure, an ejection fraction of at least 50% and a BMI of at least 30. The composite of cardiovascular death or a worsening heart-failure event occurred in 36 patients (9.9%) on tirzepatide and 56 (15.3%) on placebo (hazard ratio 0.62, 95% CI 0.41 to 0.95). The difference was driven by worsening heart-failure events (29 vs 52); cardiovascular deaths were 8 vs 5, with a wide confidence interval. The KCCQ clinical summary score improved by 6.9 points more with tirzepatide, and adverse events leading to discontinuation, mainly gastrointestinal, occurred in 6.3% vs 1.4% [8]. A cardiac-MRI substudy (106 analysable patients) found left-ventricular mass fell by 11 g and paracardiac adipose tissue by 45 mL relative to placebo, with the mass change tracking weight change [9].
What is still not known
- Functional meaning of lean-mass loss. Reviewers note that no included study measured objective physical function, and that body-composition methods differ widely [4,3].
- Small, selected substudies. The SURMOUNT-1 DXA analysis covers 160 of 2539 participants and its subgroup findings are post hoc [2]; the muscle MRI work is exploratory [5].
- Liver outcomes. The MASH histology trial was phase 2 and 52 weeks long, and missing biopsies were imputed on a placebo-like pattern [7].
- Weight versus drug effect. Several imaging changes correlated with weight loss, so the studies do not by themselves separate direct drug effects from weight-related ones [6,9].
- Funding. The SURMOUNT-1, SURPASS-3, SYNERGY-NASH and SUMMIT analyses cited here were funded by Eli Lilly [1,6,7,8].
Tirzepatide 10mg at PurixLab
Tirzepatide 10mg: a labelled lyophilized research vial with 10mg per vial, C$129 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/tirzepatide-10mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PubMed 35658024 · doi:10.1056/NEJMoa2206038
- Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. PubMed 39996356 · PMC11965027 · doi:10.1111/dom.16275
- Karakasis P, Patoulias D, Fragakis N, et al. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism. 2025;164:156113. PubMed 39719170 · doi:10.1016/j.metabol.2024.156113
- Batsis JA, Gavras A, Gross DC, et al. Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition : A Systematic Review. Ann Intern Med. 2026;179(7):996-1013. PubMed 41996180 · doi:10.7326/ANNALS-25-00478
- Sattar N, Neeland IJ, Dahlqvist Leinhard O, et al. Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2025;13(6):482-493. PubMed 40318682 · doi:10.1016/S2213-8587(25)00027-0
- Gastaldelli A, Cusi K, Fernández Landó L, et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10(6):393-406. PubMed 35468325 · doi:10.1016/S2213-8587(22)00070-5
- Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;391(4):299-310. PubMed 38856224 · doi:10.1056/NEJMoa2401943
- Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427-437. PubMed 39555826 · doi:10.1056/NEJMoa2410027
- Kramer CM, Borlaug BA, Zile MR, et al. Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy. J Am Coll Cardiol. 2025;85(7):699-706. PubMed 39566869 · doi:10.1016/j.jacc.2024.11.001